Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression

NCT01256177 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

361

Enrollment

INDUSTRY

Sponsor class

Conditions

Bipolar Depression

Interventions

DRUG: Quetiapine Fumarate (SEROQUEL) Extended Release
DRUG: Placebo

Sponsor

AstraZeneca